ClinicalTrials.gg
Not yet recruitingNCT07940647Updated Nov 17, 2026

A Safety and Tolerability Study of HJB647 in Adult Participants With Uncontrolled Hypertension

A Phase 1 interventional study of HJB647 and Placebo in Uncontrolled Hypertension, sponsored by Novartis Pharmaceuticals. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at different doses in participants with uncontrolled hypertension (uHTN)

Read the detailed description

This is a multi-center randomized, participant- and investigator-blinded, placebo-controlled study, and consists of two arms: Arm 1, followed by either Arm 2a OR Arm 2b, selected based on review of Arm 1 safety and tolerability data.

Following a screening period of up to 30 days, including a 2-week participant-blinded placebo run-in period, eligible participants will be randomized in a 3:1 ratio to receive oral HJB647 or matching placebo while continuing their background antihypertensive therapy.

02

Conditions studied

  • Uncontrolled Hypertension

Keywords

  • Uncontrolled hypertension,
  • HJB647,
  • safety
  • tolerability
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.

Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged ≥ 18 years
  • Uncontrolled hypertension despite treatment with ≥ 2 anti-hypertensive medications
  • Mean Sitting BP measured by office-based blood pressure measurement (OBPM):

    • at Screening, SBP ≥ 140 mmHg and \<180 mmHg
    • at Baseline, SBP ≥ 135 mmHg and \<180 mmHg
    • at Screening and Baseline, DBP ≥ 60 mmHg and \<110 mmHg

Exclusion criteria

Exclusion Criteria:

  • Known history of secondary hypertension.
  • Acute coronary syndrome, stroke, , acute aortic dissection, cardiac, carotid or other major cardiovascular surgery, PCI, or carotid angioplasty within the 12 months prior to Screening.
  • valvular heart disease or clinically significant cardiac arrhythmias.
  • II to IV heart failure regardless of .
  • History of hospitalization for hypertensive emergencies or hospitalization for nonemergent/ non-urgent uncontrolled hypertension without organ damage within 3 months prior to screening.
  • Use of strong inhibitors or inducers, soluble guanylate cyclase (sGC) activators (e.g. vericiguat), phosphodiesterase type 5 (PDE5) inhibitors, and nitroglycerin products.
  • Resting ≥450 msec (male) or ≥460 msec (female) at Screening and Baseline.
  • Women of unless they are using highly effective .

Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    HJB647 Arm 1

    Participants will receive oral HJB647 using a regimen corresponding to Arm 1

    Drug: HJB647

  • Placebo comparator
    Placebo Arm 1

    Participants will receive matching placebo orally using a regimen corresponding to Arm 1.

    Drug: Placebo

  • Experimental
    HJB647 Arm 2a

    Participants will receive oral HJB647 using a regimen corresponding to Arm 2a. Arm 2a will be enrolled following review of safety and tolerability data from Arm 1.

    Drug: HJB647

  • Placebo comparator
    Placebo Arm 2a

    Participants will receive matching placebo using a regimen corresponding to Arm 2a. Arm 2a will be enrolled following review of safety and tolerability data from Arm 1.

    Drug: Placebo

  • Experimental
    HJB647 Arm 2b

    Participants will receive oral HJB647 using a regimen corresponding to Arm 2b. Arm 2b will be enrolled following review of safety and tolerability data from Arm 1.

    Drug: HJB647

  • Placebo comparator
    Placebo Arm 2b

    Participants will receive matching placebo orally using a regimen corresponding to Arm 2b. Arm 2b will be enrolled following review of safety and tolerability data from Arm 1.

    Drug: Placebo

Interventions

  • DrugHJB647

    HJB647 oral capsules administered in adult participants with uncontrolled hypertension

  • DrugPlacebo

    Matching placebo capsules administered orally

06

What researchers measure

Primary outcomes

  1. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of participants with AEs and SAEs, including abnormal changes in vital signs, physical examination, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs.

    Time frame: From first dose through the arm-specific end-of-study visit, up to Day 85

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of HJB647

    Maximum observed plasma concentration of HJB647 at steady state.

    Time frame: At protocol-specified PK timepoints through Day 64

  2. Time to Maximum Observed Plasma Concentration (Tmax) of HJB647

    Time to maximum observed plasma concentration of HJB647 at steady state.

    Time frame: At protocol-specified PK timepoints through Day 64

  3. Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUCtau) of HJB647

    Area under the plasma concentration-time curve during the dosing interval at steady state.

    Time frame: At protocol-specified PK timepoints through Day 64

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Nov 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Nov 23, 2026
Primary completionEst.
Nov 5, 2027
CompletionEst.
Nov 5, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940647
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 23, 2026 (estimated)
Primary completion
Nov 5, 2027 (estimated)
Completion
Nov 5, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion